Cyclacel Announces Commencement of Investigator-Initiated Phase 2 Trial

Cyclacel Pharmaceuticals, Inc.

, today announced that the first patient has been dosed in an investigator-initiated, translational, Phase 2 clinical study at The University of Texas MD Anderson Cancer Center.